TABLE 4.

Proportion of patients who had achieved coprimary endpoints at 4 month in phase III clinical trials and current study.

ΔEASI at 4-months follow-up	MEASURE UP 1 (15 mg/day), % of patients	MEASURE UP 2 (15 mg/day), % of patients	AD UP (15 mg/day), % of patients	Current study, % of patients
EASI-75 point	69.6	60.1	64.6	80
EASI-90 point	53.1	42.4	42.8	50
EASI-100 point	16.7	14.1	–	10